CliffBio
small molecule

JENTADUETO

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Loss of exclusivityDecember 2037latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →See this company's full patent-cliff portfolio

Drug detail

Brand nameJENTADUETO
Active ingredientLINAGLIPTIN; METFORMIN HYDROCHLORIDE
Strength2.5MG;1GM
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2012
Marketing statusRX

Listed patents

PatentExpiresType
12364700*PEDDecember 2037—
12364700June 2037use U-4224
8846695*PEDDecember 2030—
9155705*PEDNovember 2030—
8846695June 2030use U-1503
9155705May 2030product
11911388April 2030use U-3854
9415016*PEDOctober 2029—
10022379*PEDOctober 2029—
10973827*PEDOctober 2029—
12678442April 2029product
10022379April 2029use U-2339
10973827April 2029product
9415016April 2029product
8673927*PEDNovember 2027—
8673927May 2027use U-1503
8883805*PEDMay 2026—
8883805November 2025product

Regulatory exclusivity

CodeExpires
PEDDecember 2026
M-295June 2026

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.